Effects of acetyl-DL-leucine in patients with cerebellar ataxia

Total Views30
File Size270.07 KB
File Typepdf
Create DateFebruary 11, 2018
Last UpdatedFebruary 14, 2018

No existing medication has yet been shown to
convincingly improve cerebellar ataxia. Therefore, the
identification of new drugs for its symptomatic treatment is
desirable. The objective of this case series was to evaluate
the efficacy of treatment of cerebellar ataxia with the
amino acid acetyl-DL-leucine (Tanganil). Thirteen patients
(eight males, median age 51 years) with degenerative
cerebellar ataxia of different etiologies (SCA1/2, ADCA,
AOA, SAOA) were treated with acetyl-DL-leucine (5 g/
day) without titration for 1 week. M